We have investigated the structural gene for adenosine deaminase (ADA) in a female infant with ADA deficiency associated severe combined immune deficiency (ADA'SCID) disease and her family by DNA restriction-fragment-length analysis. In this family a new ADA-specific restriction-fragment-length variant was detected, which involves a 3.2-kb deletion spanning the ADA promoter as well as the first exon. It was found that the patient, who was born to a consanguineous couple, was homozygous and both her parents and her brother were heterozygous for the deletion. No ADA-specific mRNA could be detected by hybridization in fibroblasts derived from this patient. Thus the patient was established to be homozygous for a true null ADA allele. In the light of the apparently normal development of most tissues except the lymphoid tissue the above finding directly questions the classification of ADA as a 'housekeeping' enzyme.
INTRODUCTION
A severe deficiency of adenosine deamlnase (ADA; E.C.3.5.4.4.) in man leads to a form of severe combined immune deficiency (SCID) disease (l.see references 2,3 for reviews). In ADA'SCID patients the proper development of both T-and B-lymphocytes is severely affected rendering them susceptible to various opportunistic Infections, most often leading to death before the age of 1 yr in the absence of proper treatment. Recently, by a selective ADA replacement using polyethylene glycol-modified ADA, Hershfield et al. (4) showed ADA deficiency to be the sole cause of the observed immune dysfunction in ADA'SCID patients. A consensus as to the basic metabolic pathways leading to the observed immune dysfunction in ADA'SCID patients still has to be reached.
The recent cloning of ADA-specific sequences enabled us and others to investigate the basic molecular defect underlying ADA deficiency. Analysis of lymphoblastoid cell lines derived from ADA"SCID patients revealed that they contained ADA-specific mRNA of normal length and in normal abundance (5) . Slnuclease analysis of RNAs from a number of these cell lines detected ab-normalities 1n only 10X of the mRNA in some of the cell lines, suggesting the occurrence of point mutations in the remainder (6) .
So far, in the ADA'SCID cell lines GM1715 and GM2471, 2 different point mutations have been identified that are deemed to be responsible for ADA deficiency; both mutations affected only one allele (7, 8) . In addition, another mutation apparently introduced during cDNA cloning was found to Inactivate ADA when introduced into an expression vector (9). All three point mutations lead to different amino acid substitutions at different positions in the protein. This wide variety of point mutations all rendering the ADA gene inactive discouraged the use of recombinant-DNA techniques in the prenatal diagnostics, as well as in carrier-detection studies in unrelated families. On the other hand, carrier status determination within a family at risk by simply determining ADA enzyme activity levels is often hampered by the fact that red cell ADA exhibits a large variation within the normal population (10). We therefore undertook a search for possible RFLPs segregating at the ADA locus to employ 1n studies on carrier detection and prenatal diagnosis in families at risk.
Whilst investigating the family of an ADA~SCID patient we detected a novel DNA restriction variant of the ADA gene due to a 3.2-kb deletion including the ADA promoter and the first exon. The infant suffering from ADA'SCID disease, born to a consanguineous couple, was found to be homozygous while both her parents and her brother are heterozygous for the deletion. No aberrant ADA-specific transcripts originating from possible cryptic promoters could be detected in cultured primary skin fibroblasts derived from the patient. These data taken together clearly suggest that this patient suffers from complete deficiency of ADA due to a true null allele. Furthermore, since all but the lymphoid tissues apparently grew and developed normally in this patient, ADA does not seem to be a 'housekeeping' enzyme in the strict sense of the word.
CASE REPORT OF THE PATIENT
The patient, a girl, was presented at the age of 2 months with feeding difficulties, diarrhoea, failure to thrive and some developmental delay. Also dysostosis was observed in this patient. In the following months, she suffered from septicaemia and pneumonia caused by Pseudomonas aeruginosa and interstitial pneumonia caused by Pneumocystis carinii. Due to anaemia she received several transfusions with erythrocyte concentrates. A severe form of congenital immune deficiency was suspected.
Immunological investigations showed severe lymphopenia, an absence of vn vitro proliferative response of blood lymphocytes and agammaglobulinaemia. ADA activity was found to be absent in her in white blood cells (see also  table I) . Therefore, the diagnosis of ADA'SCID disease was made.
At the age of 8 months she received a T-cell-depleted bone-marrow graft derived from her HLA-phenotypically identical but genotypically mismatched brother (relative response index = 30.5% in the mixed lymphocyte culture), after conditioning with antithymocyte globulins (ATG) 3x2mg/kg body weight (bw), Busulphan 4x4mg/kg bw and cyclophosphamide 4x50mg/kg bw. Cyclosporin A 2mg/kg bw was given to prevent Graft-versus-Host disease (GvHD) in continuous intravenous infusion from day -5 onwards. Haematological reconstitution was achieved within one month and immunological reconstitution within 7 months after bone marrow transplantation (BMT). The post-transplantation period was complicated by recurrent interstitial pneumonia caused by Pn. carinii, recurrent septicaemia via the deep indwelling intravenous catheder caused by Sê pidermidis and severe feeding problems because of disturbances in gastric tonus and peristaltic motility.
Ten months after BMT, at the age of 18 months, the child was discharged in good health but still needed a formula feeding by nasogastric tube. Although there was an improvement of her mental development after BMT she was still retarded at the time of discharge and her fine motor coordination continued to be impaired. .l) . However, the common 2.6-kb PvuII fragment was absent in patient DNA when screened with a cDNA probe recognizing exons 1 through 11. This 2.6-kb PvuII fragment contains the first exon of the ADA gene (our own unpublished results). The absence of these sequences was shown not to be caused by the fact that, due to a RFLP, they were now contained in a fragment of altered size and, as a result, are comigrating with other fragments hybridizing with the cDNA probe. Subsequent hybridization with a genomic probe specific for exon 1 as well as for 135 bp upstream sequences did not result in any specific hybridization to patient DNA, suggesting that exon 1 is absent, probably due to a deletion To exclude the possibility that ADA-specific RNA is transcribed from potential cryptic promoters we analysed the RNA content of primary skin fibroblasts derived from the patient. No ADA-specific RNA could be detected at any position in the lanes P containing the patient's RNA sample, even after extremely long exposure (fig 5, lane P, panels ADA o/n and ADA 2 weeks). To ascertain that the same amount of intact RNA was indeed analysed in all lanes, the same filter was rescreened with a y-act1n-spec1fic probe 5, panel actin) . From these data it became clear that the deletion of the ADA promoter does not result in the activation of cryptic promoters, if any, leading to the synthesis of aberrant RNAs. In summary, it can be concluded that this patient is homozygous for a true null allele. Furthermore, DNA analysis has unambigiously established the carrier status of both the parents and the brother.
MATERIALS AND METHODS

DISCUSSION
We found that the ADA deficiency in an ADA'SCID patient was due to a homozygous deletion involving the promoter and the first exon of the ADA-gene. In our patient the ADA protein can not be produced at all and hence one cannot postulate a residual activity which could be held responsible for the normal growth and development of cells that 1n normal individuals also express low levels of ADA. At least during her early childhood the patient had an apparently normal development of most tissues except the lymphoid system. In our opinion, this calls for a revision on the classification of ADA as a 'house-keeping enzyme' in the strict sense of the word. From the above data one can conclude that for growth and differentiation of most of the tissues except for the T-lymphocyte tissue ADA is not absolutely required. On the other hand the expression of ADA is found in all tissues from normal healthy individuals examined sofar (21) . Perhaps this expression is superfluous in almost all of the tissues with the exception of the lymphoid system.
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The determination of the molecular basis of ADA deficiency in this patient and the subsequent establishment of the carrier status by means of DNA analysis in the relatives at risk directly demonstrated the pitfalls encountered by determining carrier status just by measuring enzyme activity levels alone. On the basis of enzyme activity levels neither the parents nor the brother could be designated as carriers of an aberrant ADA allele whereas DNA analysis unequivocally indicates their carrier status. This also stresses the caution with which one has to interpret studies correlating ADA activity with chromosome 20 abnormalities in an attempt to localize the ADA gene through gene dosage studies (22,23,24,25) . Obviously the expression of the single intact allele of the heterozygotes described in this paper may very well exceed the expression of two intact alleles in some normal individuals. Therefore it is better to correlate the presence of ADA-specific DNA sequences with chromosome 20 abnormalities to localize the ADA gene.
We have mapped the 3.2-kb deletion to a 4.2-kb region around the first exon. DNA sequence analysis of this region of the ADA gene (19) , revealed the presence of 3 identically oriented full-sized Alu repeats, two of which, very suggestively, are located 3.2 kb apart (see fig. 6 ). Recently several groups have reported that Alu-Alu recombinational events can generate deletions as well as duplications in structural genes presumably through unequal crossingover (26,27,28). Possibly a recombination event involving these 3.2-kb separated Alu repeats is also responsible for the observed 3.2-kb deletion described in this report. Further studies to substantiate this hypothesis are underway.
